Theravance Biopharma, Inc. Quarterly Other Liabilities, Noncurrent in USD from Q4 2013 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Summary
Theravance Biopharma, Inc. quarterly Other Liabilities, Noncurrent history and growth rate from Q4 2013 to Q4 2024.
  • Theravance Biopharma, Inc. Other Liabilities, Noncurrent for the quarter ending December 31, 2024 was $1.89M, a 68.1% decline year-over-year.
Other Liabilities, Noncurrent, Quarterly (USD)
Other Liabilities, Noncurrent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $1.89M -$4.03M -68.1% Dec 31, 2024 10-K 2025-03-07
Q3 2024 $4.98M -$2.7M -35.2% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $4.89M -$2.79M -36.4% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $5.45M -$2.23M -29.1% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $5.92M +$4.26M +257% Dec 31, 2023 10-K 2025-03-07
Q3 2023 $7.68M +$6.02M +363% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $7.68M +$5.27M +219% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $7.68M +$5.25M +216% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $1.66M -$523K -24% Dec 31, 2022 10-K 2024-03-01
Q3 2022 $1.66M -$952K -36.5% Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $2.4M +$571K +31.2% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $2.43M +$370K +18% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $2.18M +$347K +18.9% Dec 31, 2021 10-K 2023-03-01
Q3 2021 $2.61M -$7.1M -73.1% Sep 30, 2021 10-Q 2021-11-08
Q2 2021 $1.83M -$7.78M -80.9% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $2.06M -$7.53M -78.5% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $1.83M -$19.5M -91.4% Dec 31, 2020 10-K 2022-02-28
Q3 2020 $9.7M +$804K +9.03% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $9.61M -$4.84M -33.5% Jun 30, 2020 10-Q 2020-08-10
Q1 2020 $9.58M -$4.68M -32.8% Mar 31, 2020 10-Q 2020-05-08
Q4 2019 $21.3M -$3.48M -14% Dec 31, 2019 10-K 2021-02-26
Q3 2019 $8.9M -$19.4M -68.6% Sep 30, 2019 10-Q 2019-11-08
Q2 2019 $14.5M -$13.9M -49% Jun 30, 2019 10-Q 2019-08-05
Q1 2019 $14.3M -$21.8M -60.5% Mar 31, 2019 10-Q 2019-05-10
Q4 2018 $24.8M -$10.1M -28.9% Dec 31, 2018 10-K 2020-02-27
Q3 2018 $28.3M +$1.83M +6.92% Sep 30, 2018 10-Q 2018-11-08
Q2 2018 $28.3M +$9.33M +49.1% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 $36.1M +$17.6M +95.1% Mar 31, 2018 10-Q 2018-05-09
Q4 2017 $34.8M +$21.7M +166% Dec 31, 2017 10-K 2019-02-28
Q3 2017 $26.5M +$17.6M +199% Sep 30, 2017 10-Q 2017-11-08
Q2 2017 $19M +$15.1M +390% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $18.5M +$14.8M +395% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 $13.1M +$10.1M +340% Dec 31, 2016 10-K 2018-02-28
Q3 2016 $8.85M +$6.06M +218% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $3.88M +$1.45M +59.4% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $3.74M +$1.85M +97.8% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 $2.98M +$1.41M +89% Dec 31, 2015 10-K 2017-03-01
Q3 2015 $2.79M +$1.8M +182% Sep 30, 2015 10-Q 2015-11-12
Q2 2015 $2.43M Jun 30, 2015 10-Q 2015-08-13
Q1 2015 $1.89M Mar 31, 2015 10-Q 2015-05-13
Q4 2014 $1.58M +$993K +170% Dec 31, 2014 10-K 2016-03-11
Q3 2014 $986K Sep 30, 2014 10-Q 2014-11-12
Q4 2013 $585K Dec 31, 2013 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.